INSTITUT PASTEUR

SpikImm signed an exclusive worldwide licensing agreement with SATT Conectus for potent monoclonal antibodies targeting BK virus, addressing a critical unmet need in transplant medicine.

Oncovita's MVdeltaC, a genetically modified measles virus immunotherapy, has received FDA Orphan Drug Designation for treating pleural mesothelioma, a rare and aggressive cancer affecting approximately 3,000 Americans annually.

Sensorion has enrolled the final patient in its NOTOXIS Phase 2a trial evaluating SENS-401 for preventing hearing loss caused by cisplatin chemotherapy, with 47 patients randomized across treatment and control groups.

Argobio and Institut Pasteur have launched Enodia Therapeutics, a French biotech developing first-in-class treatments targeting the Sec61/translocon complex for protein degradation.

Initiating antiretroviral therapy (ART) within weeks of HIV infection may allow for long-term viral control even after treatment is stopped, according to a new study.